Payers

MRD Testing Moves From Prognosis Toward Treatment Action

Colon Cancer Immunotherapy Moves Into the Adjuvant Access Test

Narcolepsy Treatment Starts Targeting the Cause

AstraZeneca’s Baxfendy opens a new front in uncontrolled hypertension, but monitoring will decide who benefits

Huntington’s Gene Therapy Moves Back Toward the FDA Door

Precision cardiology is becoming the new oncology. Policy and reimbursement must catch up

CAR-T Starts Moving From Factory Medicine to In-Patient Engineering

Cellular Reprogramming Enters Neuro-Ophthalmology

Surviving Cancer Is Not the Same as Being Recovered
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
